Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H16N4O2 |
| Molecular Weight | 308.3345 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N(C(=O)C(NC(=O)C2=CC=CN=C2)=C1C)C3=CC=CC=C3
InChI
InChIKey=BRZANEXCSZCZCI-UHFFFAOYSA-N
InChI=1S/C17H16N4O2/c1-12-15(19-16(22)13-7-6-10-18-11-13)17(23)21(20(12)2)14-8-4-3-5-9-14/h3-11H,1-2H3,(H,19,22)
| Molecular Formula | C17H16N4O2 |
| Molecular Weight | 308.3345 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14133613Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/24954054
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14133613
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/24954054
Nifenazone is a drug that has been used as an analgesic for a number of rheumatic conditions. Later it was shown that nifenazone is not of significant value in the therapy of the chronic rheumatic disorders and that side-effects may be expected to occur, particularly in those patients who give a history of abnormal reactions to phenylbutazone and oxyphenbutazone.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The solvatochromic, spectral, and geometrical properties of nifenazone: a DFT/TD-DFT and experimental study. | 2014-08-07 |
|
| Evaluation of liver function during administration of nifenazone in rheumatic disease on the basis of serum protein studies and enzyme tests. | 1972-04-01 |
|
| TRIAL OF NIFENAZONE ("THYLIN"). | 1964-06-13 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14133613
750 - 2,000 mg. daily, orally in divided dosage.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:14:49 GMT 2025
by
admin
on
Mon Mar 31 18:14:49 GMT 2025
|
| Record UNII |
8780F0K71U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
||
|
WHO-VATC |
QM02AA24
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
||
|
WHO-ATC |
N02BB05
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
||
|
WHO-ATC |
M02AA24
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
||
|
WHO-VATC |
QN02BB05
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2139-47-1
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
m368
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | Merck Index | ||
|
4487
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
SUB09256MIG
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
758411
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
C005249
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
100000084422
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
8780F0K71U
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
CHEMBL1413176
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
218-387-1
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
Nifenazone
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
C76806
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
1834
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
DTXSID7045366
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
DB13407
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY | |||
|
1924
Created by
admin on Mon Mar 31 18:14:49 GMT 2025 , Edited by admin on Mon Mar 31 18:14:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |